Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Cancer Clinical Trials Approvals

Three key ingredients for Bayer's future growth

This article was originally published in Scrip

Executive Summary

Three projects that will drive future growth were highlighted at Bayer's Perspective on Innovation 2014 Meeting, held in Leverkusen on 2 December 2014. The company singled out the protein free formulation of its blockbuster hemophilia A therapy Kogenate (BAY 81-8973), regorafenib eye drops for wet age-related macular degeneration, and the androgen receptor inhibitor ODM-201, which is partnered with Orion.

Table

View full table

Topics

Related Companies

Tags:
Cancer Clinical Trials Approvals
Latest Headlines

Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara

Humira Market Erosion Is Continuing As Expected, AbbVie Says

Pfizer Matches Beqvez Price To Hemgenix In Hemophilia B, Plans Warranty Program

Analysis: Novo And Lilly Make Their Money Work

See All
UsernamePublicRestriction

Register

SC027115

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By